Methylnaltrexone Bromide Articles
Progenics Pharma grants rights to Salix for Relistor, in upfront $60 million and potential $290 million more deal
8 February 2011
Scottish regulators give nod to Bayer's Xarelto, Wyeth's Relistor and B-MS' Reyataz
15 December 2008
Strong Ph III for Relistor in non-cancer OIC
8 December 2008
Progenics gets Australian appro for Relistor
24 November 2008
Ono licenses Progenics' OIC drug in Japan
27 October 2008
Japan MHLW Study C'ttee views developments
13 October 2008
US FDA set for even fewer approvals in 2008
1 September 2008
Wyeth/Progenics' Reslitor approved in EU
14 July 2008
Ph III data for Wyeth's Relistor injection
9 June 2008
FDA approves Wyeth & Progenics' Relistor
5 May 2008
Showing 1-14 of 14 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
